US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

Actinium Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
us-stock
$1.45 0.0507(5.07%) ATNM at 04 Dec 2025 04:26 PM Biotechnology
Lowest Today 1.38
Highest Today 1.47
Today’s Open 1.38
Prev. Close 1.38
52 Week High 2.41
52 Week Low 1.03
Day’s Range: Low 1.38 High 1.47
52-Week Range: Low 1.03 High 2.41
1 day return -
1 Week return +5.03
1 month return +7.35
3 month return -14.11
6 month return -14.36
1 year return +21.66
3 year return -86.4
5 year return -86.5
10 year return -

Institutional Holdings

Market Status

Strong Buy: 2

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 43.05 M

PB Ratio 3.1006

PE Ratio 0.0

Enterprise Value -9.51 M

Total Assets 76.90 M

Volume 151031

Company Financials

Annual Revenue FY23:0 0.0M, FY22:1030000 1.0M, FY21:1144000 1.1M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:1030000 1.0M, FY21:1144000 1.1M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-50141000 -50.1M, FY22:-31930000 -31.9M, FY21:-24584000 -24.6M, FY20:-22037000 -22.0M, FY19:-21726661 -21.7M

Quarterly Revenue Q3/2025:90000 0.1M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-116000 -0.1M, Q2/2025:-204000 -0.2M, Q1/2025:-205000 -0.2M, Q3/2024:null 0.0M, Q2/2024:-189000 -0.2M

Quarterly Net worth Q3/2025:-5131000 -5.1M, Q2/2025:-6878000 -6.9M, Q1/2025:-15938000 -15.9M, Q3/2024:-11568000 -11.6M, Q2/2024:-11353000 -11.4M

Fund house & investment objective

Company Information Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Organisation Biotechnology

Employees 25

Industry Biotechnology

CEO Mr. Sandesh C. Seth M.B.A., M.S.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right